Sunday - July 6, 2025
Johnson & Johnson: Imbruvica Receives Positive European Opinion for Mantle Cell Lymphoma Treatment
June 20, 2025
NEW BRUNSWICK, New Jersey, June 20 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

IMBRUVICA(r) (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant

*

BEERSE, BELGIUM (20 June 2025) - Janssen-Cilag International NV, a Johnson & Johnson company, today announced t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products